European Hematology Association Annual Meeting EHA
Posted: Tue Feb 18, 2025 4:58 am
Although Ascentage Medical was founded in 2009, its founding team has more than 20 years of research and development history in the field of apoptosis, and has made indepth layouts on the Bcl2 target. The company's core product, Bcl2 inhibitor APG2575, is also the first domestically developed Bcl2 inhibitor to submit NDA in China, and is expected to become the second approved Bcl2 inhibitor in the world.
In addition, the company's core product, Narica, for the treatment of chronic myeloid leukemia has also been approved in China, making it its first marketed product. As a Chinese original innovative drug with BIC potential, Narica has attracted much attention from the global hematology community, and its clinical progress has been selected for oral presentations at the ASH Annual Meeting for seven consecutive years.
Ascentage Pharma's R&D capabilities have been widely recognized and malaysia phone number list demonstrated around the world. Looking at this year alone, many clinical advances of its products such as Narica, APG2575, and APG2449 were showcased at multiple international academic conferences in , including the American Society of Clinical Oncology ASCO Annual Meeting, the , and the American Association for Cancer Research Annual Meeting AACR.
These conferences are the most important academic exchange platforms in the global oncology field. Ascentage Pharma has been able to showcase its research results at these conferences for many consecutive years, which is sufficient to demonstrate its strong R&D capabilities and international influence.
In addition, the company's core product, Narica, for the treatment of chronic myeloid leukemia has also been approved in China, making it its first marketed product. As a Chinese original innovative drug with BIC potential, Narica has attracted much attention from the global hematology community, and its clinical progress has been selected for oral presentations at the ASH Annual Meeting for seven consecutive years.
Ascentage Pharma's R&D capabilities have been widely recognized and malaysia phone number list demonstrated around the world. Looking at this year alone, many clinical advances of its products such as Narica, APG2575, and APG2449 were showcased at multiple international academic conferences in , including the American Society of Clinical Oncology ASCO Annual Meeting, the , and the American Association for Cancer Research Annual Meeting AACR.
These conferences are the most important academic exchange platforms in the global oncology field. Ascentage Pharma has been able to showcase its research results at these conferences for many consecutive years, which is sufficient to demonstrate its strong R&D capabilities and international influence.